New hope for Wegener's patients: drug aims to stop flare-ups
NCT ID NCT06940661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called obinutuzumab in 33 adults with a relapsing form of granulomatosis with polyangiitis (GPA, formerly Wegener's). The goal is to see if the drug can stop disease activity and turn off the related antibody. Participants will be followed for 6 months to check for remission and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Médecine Interne, Centre de reference "Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques"
RECRUITINGParis, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Promising vasculitis drug trial halted early
- Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
- New hope for rare vasculitis: Three-Drug trial targets Non-Responders
- Steroid showdown: can a tiny daily dose keep a rare disease at bay?
- Could a 4-Week steroid course be safer for vasculitis patients?
- Could a tiny dose of naltrexone ease vasculitis symptoms?